The ATLAS Study: A Clinical Trial for Adults with a Confirmed Superoxide Dismutase 1 (SOD1) Mutation without Signs or Symptoms of Amyotrophic Lateral Sclerosis (ALS)

The purpose of this webinar is to provide an overview of the ATLAS study, the investigational drug, eligibility criteria, and what study participation involves. This webinar will also share resources for interested individuals to learn more about study participation. This webinar will be held live on March 17, 2022.

Michael Benatar, MD, PhD Professor of Neurology, the Walter Bradley Chair in ALS Research, and Executive Director of the ALS Center at the University of Miami